The Drugs Controller General of India (DCGI) has permitted Bharat Biotech to give a third dose of Covaxin to a few volunteers in its clinical trials of the Covid-19 vaccine, sources said.
Bharat Biotech presented amendments to the subject expert committee of the DCGI in the approved Phase 2 clinical trials protocol for administration of booster dose six months after second dose.
The SEC said after a detailed deliberation, the committee recommended that the firm should conduct the booster dose study only in 6 mcg cohort and also should follow up the subjects at least for six months after the third dose.
Further the Bharat Biotech was asked to present the details of the primary and secondary objectives and various assessments to be carried out in the subjects.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…